Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases

OBJECTIVE: To compare baseline characteristics, clinical presentations and outcomes of patients with rheumatic conditions requiring hospitalization for coronavirus disease 2019 (COVID-19) who received chronic HCQ with those who did not receive chronic HCQ. METHODS: We identified all patients with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pham, Khanh, Torres, Heidi, Satlin, Michael J, Goyal, Parag, Gulick, Roy M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989153/
https://www.ncbi.nlm.nih.gov/pubmed/33875975
http://dx.doi.org/10.1093/rap/rkab014
_version_ 1783668903644233728
author Pham, Khanh
Torres, Heidi
Satlin, Michael J
Goyal, Parag
Gulick, Roy M
author_facet Pham, Khanh
Torres, Heidi
Satlin, Michael J
Goyal, Parag
Gulick, Roy M
author_sort Pham, Khanh
collection PubMed
description OBJECTIVE: To compare baseline characteristics, clinical presentations and outcomes of patients with rheumatic conditions requiring hospitalization for coronavirus disease 2019 (COVID-19) who received chronic HCQ with those who did not receive chronic HCQ. METHODS: We identified all patients with a rheumatologic disease who were admitted with COVID-19 to two hospitals in New York City between 3 March 3 and 30 April 2020. Patients who received chronic HCQ prior to admission were matched 1:2 (±10 years of age) with patients who did not receive chronic HCQ. We compared demographics, comorbidities, HCQ dosages, concurrent medications, presentations and outcomes between the groups. RESULTS: There were 14 patients receiving HCQ and 28 matched control subjects. The median age of cases was 63 years [interquartile range (IQR) 43–73) and 60 years (IQR 41–75) for controls. Control subjects had a higher prevalence of pulmonary diseases (42.8%), diabetes (35.7%) and obesity (35.7%) than their case counterparts (28.6%, 14.3% and 7.1%, respectively). A higher proportion of cases than control subjects (50% vs 25%) reported the use of prednisone for their rheumatic conditions prior to admission. Despite these differences in baseline characteristics, univariate logistic regression revealed no statistically significant differences in the need for mechanical ventilation [OR 1.5 (95% CI 0.34, 6.38)] or in-hospital mortality [OR 0.77 (95% CI 0.13, 4.56)]. CONCLUSION: HCQ therapy in individuals with rheumatic conditions was not associated with less severe presentations of COVID-19 among hospitalized patients compared with individuals with rheumatic conditions not receiving HCQ.
format Online
Article
Text
id pubmed-7989153
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-79891532021-04-01 Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases Pham, Khanh Torres, Heidi Satlin, Michael J Goyal, Parag Gulick, Roy M Rheumatol Adv Pract Concise Report OBJECTIVE: To compare baseline characteristics, clinical presentations and outcomes of patients with rheumatic conditions requiring hospitalization for coronavirus disease 2019 (COVID-19) who received chronic HCQ with those who did not receive chronic HCQ. METHODS: We identified all patients with a rheumatologic disease who were admitted with COVID-19 to two hospitals in New York City between 3 March 3 and 30 April 2020. Patients who received chronic HCQ prior to admission were matched 1:2 (±10 years of age) with patients who did not receive chronic HCQ. We compared demographics, comorbidities, HCQ dosages, concurrent medications, presentations and outcomes between the groups. RESULTS: There were 14 patients receiving HCQ and 28 matched control subjects. The median age of cases was 63 years [interquartile range (IQR) 43–73) and 60 years (IQR 41–75) for controls. Control subjects had a higher prevalence of pulmonary diseases (42.8%), diabetes (35.7%) and obesity (35.7%) than their case counterparts (28.6%, 14.3% and 7.1%, respectively). A higher proportion of cases than control subjects (50% vs 25%) reported the use of prednisone for their rheumatic conditions prior to admission. Despite these differences in baseline characteristics, univariate logistic regression revealed no statistically significant differences in the need for mechanical ventilation [OR 1.5 (95% CI 0.34, 6.38)] or in-hospital mortality [OR 0.77 (95% CI 0.13, 4.56)]. CONCLUSION: HCQ therapy in individuals with rheumatic conditions was not associated with less severe presentations of COVID-19 among hospitalized patients compared with individuals with rheumatic conditions not receiving HCQ. Oxford University Press 2021-03-02 /pmc/articles/PMC7989153/ /pubmed/33875975 http://dx.doi.org/10.1093/rap/rkab014 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Concise Report
Pham, Khanh
Torres, Heidi
Satlin, Michael J
Goyal, Parag
Gulick, Roy M
Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases
title Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases
title_full Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases
title_fullStr Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases
title_full_unstemmed Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases
title_short Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases
title_sort failure of chronic hydroxychloroquine in preventing severe complications of covid-19 in patients with rheumatic diseases
topic Concise Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989153/
https://www.ncbi.nlm.nih.gov/pubmed/33875975
http://dx.doi.org/10.1093/rap/rkab014
work_keys_str_mv AT phamkhanh failureofchronichydroxychloroquineinpreventingseverecomplicationsofcovid19inpatientswithrheumaticdiseases
AT torresheidi failureofchronichydroxychloroquineinpreventingseverecomplicationsofcovid19inpatientswithrheumaticdiseases
AT satlinmichaelj failureofchronichydroxychloroquineinpreventingseverecomplicationsofcovid19inpatientswithrheumaticdiseases
AT goyalparag failureofchronichydroxychloroquineinpreventingseverecomplicationsofcovid19inpatientswithrheumaticdiseases
AT gulickroym failureofchronichydroxychloroquineinpreventingseverecomplicationsofcovid19inpatientswithrheumaticdiseases